Results: Of the 12 identified articles in analyzing cost-effectiveness, there are 9 articles using palbociclib + letrozole, accounting for 75.0%; 1 article indicating palbociclib + fulvestrant, 1 article having letrozole / fulvestrant with palbociclib and the last article using palbociclib simultaneously with chemotherapy.